Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Illuminate
NCT07870681Phase 3Not yet recruiting
- Sponsor
- Oslo University Hospital
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Placebo with Tocilizumab (2 arms). Primary endpoint: Infarct growth on brain MRI at 72 hours. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07870681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870681.